Smooth muscle-specific drug targets for next-generation drug-eluting stent.

Abstract

The occurrence of stent thrombosis is one of the major obstacles limiting the long-term clinical efficacy of percutaneous coronary intervention. The anti-smooth muscle proliferation drugs coated on drug-eluting stents (DES) often indistinguishably block re-endothelialization, an essential step toward successful vascular repair, due to their nonspecific effect on endothelial cells (ECs). Therefore, identification of therapeutic targets that differentially regulate vascular smooth muscle cell (VSMC) and EC proliferation may lead to the development of ideal drugs for the next-generation DES. Our recent studies have shown that CTP synthase 1 (CTPS1) differentially regulates the proliferation of VSMC and EC after vascular injury. Therefore, CTPS1 inhibitors are promising agents for DES. In addition to CTPS1, other factors have also shown cell-specific effects on VSMC and/or EC proliferation and thus may become potential molecular targets for developing drugs to coat stents.

• Authors: Rui Tang, Shi-You Chen
• Journal: Expert review of cardiovascular therapy (Expert Rev Cardiovasc Ther) Vol. 12 Issue 1 Pg. 21-3 (Jan 2014) ISSN: 1744-8344 [Electronic] England
• PMID: 24325297 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Chemical References

• Sirolimus

Topics

• Coronary Restenosis (therapy)
• Drug-Eluting Stents
• Endothelial Cells (drug effects)
• Humans
• Muscle, Smooth, Vascular (drug effects)
• Myocytes, Smooth Muscle (drug effects)
• Sirolimus (therapeutic use)